BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...$15M series E Feb 2012 - $50M IPO on Euronext MDxHealth S.A. (Euronext:MDXH) (formerly OncoMethylome Sciences S.A....
BioCentury | Jan 17, 2011
Company News

Exact Sciences, MDxHealth deal

...MDxHealth (formerly OncoMethylome Sciences S.A. ) received an undisclosed milestone payment from Exact Sciences under a 2010 deal...
BioCentury | Oct 25, 2010
Company News

MDxHealth diagnostic news

...its previously announced plans to shift its focus to commercial diagnostics and pharmacogenetics. MDxHealth, formerly OncoMethylome Sciences S.A....
BioCentury | Oct 4, 2010
Company News

OncoMethylome, GlaxoSmithKline deal

...the biomarker to develop a diagnostic for its immunotherapy program. Financial terms were not disclosed. OncoMethylome Sciences S.A....
BioCentury | Sep 6, 2010
Company News

OncoMethylome, Roche deal

...will compare Avastin plus current standard-of-care (SOC) vs. SOC alone. Financial terms were not disclosed. OncoMethylome...
...Roche markets it elsewhere. Avastin is a humanized mAb against vascular endothelial growth factor (VEGF). OncoMethylome Sciences S.A....
BioCentury | Sep 6, 2010
Company News

OncoMethylome diagnostic news

...OncoMethylome will initially focus on developing stand-alone molecular diagnostics based on its DNA methylation technology. OncoMethylome...
...cancer blood-based screening test and related biomarkers and close its Netherlands facility by year end. OncoMethylome...
...additional details on the strategy in the next four to six weeks. At June 30, OncoMethylome...
BioCentury | Aug 2, 2010
Company News

Exact Sciences, OncoMethylome deal

...test in October. Exact Sciences also received non-exclusive rights to use an undisclosed part of OncoMethylome's...
...receive milestones, plus royalties. Further terms were not disclosed. Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. OncoMethylome Sciences S.A....
BioCentury | Apr 19, 2010
Company News

OncoMethylome management update

OncoMethylome Sciences S.A. (Euronext:ONCOB), Liege, Belgium Business: Diagnostic Hired: Jan Groen as CEO and a director, previously president of Agendia Inc. and COO of parent company Agendia B.V. WIR Staff Diagnostic...
BioCentury | Apr 12, 2010
Company News

OncoMethylome names Groen CEO

...Diagnostic company OncoMethylome Sciences S.A. (Euronext:ONCOB) hired Jan Groen as CEO and a director. Previously, Groen was COO...
...Agendia B.V. (Amsterdam, the Netherlands). He replaces interim CEO Philip Devine, who will remain CFO. OncoMethylome...
BioCentury | Nov 9, 2009
Company News

OncoMethylome management update

OncoMethylome Sciences S.A. (Euronext:ONCOB), Liege, Belgium Business: Diagnostic Retiring: Founder Herman Spolders as CEO, effective Jan. 1, while remaining a director; CFO Philip Devine will serve as interim CEO WIR Staff Diagnostic...
Items per page:
1 - 10 of 70
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...$15M series E Feb 2012 - $50M IPO on Euronext MDxHealth S.A. (Euronext:MDXH) (formerly OncoMethylome Sciences S.A....
BioCentury | Jan 17, 2011
Company News

Exact Sciences, MDxHealth deal

...MDxHealth (formerly OncoMethylome Sciences S.A. ) received an undisclosed milestone payment from Exact Sciences under a 2010 deal...
BioCentury | Oct 25, 2010
Company News

MDxHealth diagnostic news

...its previously announced plans to shift its focus to commercial diagnostics and pharmacogenetics. MDxHealth, formerly OncoMethylome Sciences S.A....
BioCentury | Oct 4, 2010
Company News

OncoMethylome, GlaxoSmithKline deal

...the biomarker to develop a diagnostic for its immunotherapy program. Financial terms were not disclosed. OncoMethylome Sciences S.A....
BioCentury | Sep 6, 2010
Company News

OncoMethylome, Roche deal

...will compare Avastin plus current standard-of-care (SOC) vs. SOC alone. Financial terms were not disclosed. OncoMethylome...
...Roche markets it elsewhere. Avastin is a humanized mAb against vascular endothelial growth factor (VEGF). OncoMethylome Sciences S.A....
BioCentury | Sep 6, 2010
Company News

OncoMethylome diagnostic news

...OncoMethylome will initially focus on developing stand-alone molecular diagnostics based on its DNA methylation technology. OncoMethylome...
...cancer blood-based screening test and related biomarkers and close its Netherlands facility by year end. OncoMethylome...
...additional details on the strategy in the next four to six weeks. At June 30, OncoMethylome...
BioCentury | Aug 2, 2010
Company News

Exact Sciences, OncoMethylome deal

...test in October. Exact Sciences also received non-exclusive rights to use an undisclosed part of OncoMethylome's...
...receive milestones, plus royalties. Further terms were not disclosed. Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. OncoMethylome Sciences S.A....
BioCentury | Apr 19, 2010
Company News

OncoMethylome management update

OncoMethylome Sciences S.A. (Euronext:ONCOB), Liege, Belgium Business: Diagnostic Hired: Jan Groen as CEO and a director, previously president of Agendia Inc. and COO of parent company Agendia B.V. WIR Staff Diagnostic...
BioCentury | Apr 12, 2010
Company News

OncoMethylome names Groen CEO

...Diagnostic company OncoMethylome Sciences S.A. (Euronext:ONCOB) hired Jan Groen as CEO and a director. Previously, Groen was COO...
...Agendia B.V. (Amsterdam, the Netherlands). He replaces interim CEO Philip Devine, who will remain CFO. OncoMethylome...
BioCentury | Nov 9, 2009
Company News

OncoMethylome management update

OncoMethylome Sciences S.A. (Euronext:ONCOB), Liege, Belgium Business: Diagnostic Retiring: Founder Herman Spolders as CEO, effective Jan. 1, while remaining a director; CFO Philip Devine will serve as interim CEO WIR Staff Diagnostic...
Items per page:
1 - 10 of 70